BioCentury | May 18, 2018
Financial News

Imprimis spinout Surface raises $20M series A

...transferred to Surface. In 4Q17, Imprimis transferred its three ocular surface disease candidates -- SURF-100, SURF-200...
...mycophenolic acid that uses the company's Klarity delivery vehicle to treat chronic dry eye disease. SURF-200...
...using acid-resistant capsule technology to treat refractory dry eye disease. Surface Pharmaceuticals Inc., Pleasanton, Calif. Sandi Wong SURF-100 SURF-200 SURF-300 Imprimis...
BioCentury | May 15, 2018
Financial News

Imprimis spinout Surface raises $20M series A

...transferred to Surface. In 4Q17, Imprimis transferred its three ocular surface disease candidates -- SURF-100, SURF-200...
...mycophenolic acid that uses the company's Klarity delivery vehicle to treat chronic dry eye disease. SURF-200...
...treat refractory dry eye disease. Imprimis was up $0.15 to $2.40 on Tuesday. Sandi Wong Imprimis Pharmaceuticals Inc. SURF-100 SURF-200 SURF-300 Surface...
Items per page:
1 - 2 of 2